Schistosomiasis Talks at the ASTMH 2021 Annual Meeting

Session 9 – Integrated Control Measures for NTDs - Meeting Room 8 (08:00 – 09:45) 

• 08:40 –Effect of COVID-19 risk mitigation measures on the coverage of mass treatment campaigns against schistosomiasis and vitamin A supplementation in the regions of Kayes and Segou in Mali 2020.  
• 08:50 – Evaluating the adoption of COVID-19 prevention measures during mass drug administration in Anambra State, Nigeria. 

Session 11 Schistosomiasis I – Meeting Room 10 (08:00 - 09:45) 

• 08:00 - Lesions of Female Genital Schistosomiasis are associated with the presence of live works as indicated by circulating anodic antigen testing. 
• 08:10 – Village, household, and individual level predictors of bovine schistosomiasis infection in rural villages of Sichuan, China. 
• 08:20 – The sensitivity of Schistosoma mansoni cercariae to chlorine. 
• 08:30 – Development of a multiplex bead assay for detection of antibodies against Schistosoma mansoni infection. 
• 08:40 Rapid parasite DNA amplification using a dipstick with LAMP assay.  
• 08:50 – Validation of the isothermal Recombinase Polymerase Amplification (RPA) assay for the point-of-care molecular diagnosis of female genital schistosomiasis using cervicovaginal lavage and vaginal self-swab samples. 
• 09:00 – Identification of Novel Therapeutics Against Human Schistosomiasis. 

Session 36 American Committee of Molecular, Cellural and Immuno-parasitology (ACMCIP) Parasite Immunology – New Approaches – Meeting Room 9 (15:00 – 16:45) 

• 15:00 – Maternal Schistosomiasis Reduces Humoral Immunity of Offspring via Dysfunctional B Cell Progenitor Maturation and Receptor Editing.  

Session 37 – The Neglected Intersection between Tropical Medicine and Sexual and Reproductive Health: A path towards equity, integration, and sustainability – Meeting Room 10 (15:00 – 16:45)  

• 15:10 - Introduction 
• 15:35 – Female genital schistosomiasis and STH deworming.  
• 16:06 – The “Unusual Suspects” – Innovative cross-sectoral partnerships for FGS integration.  

Session 87 – Global Health: Malaria and Neglected Tropical Diseases – Meeting Room 5 (08:00 – 09:45) 

• 08:40 – Identification of snails and Schistosoma of medical importance via convolutional neural networks.

Session 99 – Schistosomiasis II – Meeting Room 3 (12:45 – 14:30) 

• 12:45 – Effects of Schistosoma mansoni and Praziquantel treatment on the gastrointestinal mucosa: A cohort study in rural Tanzania. 
• 12:55 – Host tissue proteomics reveal insights into the molecular basis of Schistosoma haematobium-induced bladder pathology.  
• 13:05 – Host metabolic alterations form early Schistosoma haematobium infection in preschool-aged children.  
• 13:15 – In utero metabolic responses to maternal S. japonicum occur in a sex-dependent manner. 
• 13:25 – The role of microbial translocation in the pathogenesis of S. japonicum associated morbidity.  
• 13:35 – Intranasal Administration of an Adenovirus-vector Expressing Cathepsin B Protects from schistosomiasis infection in a pre-clinical model 
• 13:45 – Diminishing cross-reactivity in schistosomiasis serology by applying a single glycan target approach.

Session 107 – Schistosomiasis Morbidity Indicators for Redefining Control and Elimination as a public health problem: Findings of MORBID Pilot Study – Meeting Room 11 (12:45 – 14:30)  

• 12:55 – In Memoriam 
• 13:00 – Associations between morbidity and infection in historical monitoring and evaluation cohorts. 
• 13:20 - MORBID Kenya: Some observations from a pilot study on abdominal ultrasound and other morbidity markers in a field investigation of schistosomiasis-related morbidity at the community level in western Kenya. 
• 13:40 – MORBID Malawi: results, interpretations, and next steps.  
• 14:00 – MORBID sub-study: Female Genital Schistosomiasis in Malawi – Pilot study in two schistosome haematobium endemic settings.

Session 108 - Improving Reverse Logistics of the Last Mile Supply Chain for NTD Medicines in Endemic Areas: Lessons Learned and Best Practices – Meeting Room 1 (15:00 – 16:45) 

• 15:10 – Ghana’s experience in reverse logistics: Best practices related to NTD medicines and commodities management in an integrated national health system.  
• 15:30 – Cote D’Ivoire experience and challenges regarding reverse logistics.  
• 15:50 Kenya’s use of the District NTD Medicine inventory Tracking Tool to improve downstream reverse logistics data flow.  
• 16:10 – Findings of analysis in the PZQ tablet distribution, tracking and reporting, in support of a phased process to cover existing gaps, increase medicine accountability and improve reporting processes.